You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Expanded Clinical Validation and Commercial Launch of the UriSeq Platform for Bladder Cancer

    SBC: Convergent Genomics, Inc.            Topic: NCI

    Bladder cancer is the 5th most prevalent cancer with over 700,000 people living with the disease in the US. The disease has a particularly high patient burden as it recurs in 70% of patients following initial treatment. Over half of these patients do not respond or progress while on treatment or surveillance. New therapeutic and diagnostic options are needed for patients undergoing diagnosis and r ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells

    SBC: UBIVAC, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) and their collaborators have investigated additional tr ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. ST-246 treatment of smallpox vaccine-related adverse events

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Naturally occurring smallpox has been eradicated but remains a credible threat to the security of the United States due to its potential use as an agent of terror or biowarfare. Given that approximately 25% of the population is contraindicated to receive the vaccine due to direct risk of adverse events or the possibility of placing direct contacts at risk (23), ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    Abstract: Multiple Sclerosis (MS) is the most common neurologic disabling disease among young adults, affecting over 400,000 people in the United States and 2.5 million worldwide. Most MS individuals are initially diagnosed with relapsing-remitting MS (RRMS) and then eventually transition to secondary progressive MS (SPMS). When MS individuals enter SPMS, neurologic deficits progressively worsen o ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. A CD8+ T cell diagnostic to identify children with pulmonary tuberculosis

    SBC: ViTi, Inc            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB disease which results from infection with Mycobacterium tuberculosis Mtb is a leading cause of infectious morbidity and mortality in children andlt years old worldwide In TB endemic regions in which the vast majority of the worldandapos s annual million adult cases of TB disease reside children andlt years old account for ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Factor XII Inhibitor for Surface Initiated Thrombosis

    SBC: ARONORA INC            Topic: NHLBI

    Project Summary Certain life-saving interventions such as cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), hemodialysis, or ventricular assist device (VAD) pumps require the use of heparin to maintain blood flow through the devices and/or to prevent downstream thromboembolic complications. Several other invasive vascular procedures also utilize temporal anticoagulation, su ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. IMPROVEMENT TO OZONATING WATER FOR POST-HARVEST WASHING THROUGH NANOBUBBLES

    SBC: En Solucion Inc            Topic: FDA

    Abstract. As consumer demand for fresh produce continues to grow, so do concerns by the Food and Drug Administration (FDA) about foodborne illnesses and foodborne disease outbreaks. Postharvest wash is a critical control point in fresh produce processing for reducing or eliminating pathogens and other field-acquired contaminants that can result in such outbreaks. Current methods of post-harvest wa ...

    SBIR Phase II 2020 Department of Health and Human ServicesFood and Drug Administration
  8. Robust Predictor of Breast Cancer Risk

    SBC: Morgan and Mendel Genomics, Inc.            Topic: NCI

    SUMMARY Approximately 1.5 million women in the United States are at high-risk for developing breast cancer, based on inheritance of a germline mutation in a gene in the double strand-break (DSB) repair and cyclin-checkpoint pathways. Many are unaware of their genetic predispositions, because their family history is uninformative or unknown. Genetic testing is important for identifying mutations in ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Developing a novel, non-hormonal treatment paradigm for vaginal dryness in breast cancer survivors

    SBC: MADORRA INC.            Topic: 102

    Abstract The goal of this Fast-Track SBIR is to demonstrate the safety and efficacy of a therapeutic-ultrasound-based medical device to treat the symptoms of vaginal dryness for breast cancer survivors and postmenopausal women. Todayandapos;s best treatments for vaginal dryness all involve the use of hormones; yet, hormonal treatments are contraindicated for the 1.4 million breast cancer survivors ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. A Single-cell Platform for Analyzing the Peripheral Immune Response in Alzheimer’s and Alzheimer’s Related Diseases

    SBC: ISOPLEXIS CORPORATION            Topic: NIA

    With this Phase II submission, IsoPlexis will develop an automated system to evaluate the combined peripheral immune response of T cells and monocyte cells to differentiate and monitor neurodegenerative diseases (ND) including Alzheimer’s (AD), Frontotemporal Dementia (FTD), and Multiple Sclerosis (MS). Monitoring disease progression and treatment impact on the immune response currently requires ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government